The present invention provides dosing regimens for administering pharmacological chaperones to a subject in need thereof. The dosing regimens can be used to treat disorders caused by improper protein misfolding, such as lysosomal storage disorders.

The present invention provides dosing regimens for administering pharmacological chaperones to a subject in need thereof. The dosing regimens can be used to treat disorders caused by improper protein misfolding, such as lysosomal storage disorders.

The present invention provides methods of improving cognitive and motor deficits associated with central nervous system (CNS) disorder or condition in an animal. The methods comprise a general administration of phosphodiesterase 4 inhibitors and optionally training the animal under conditions sufficient to produce an improvement in performance.

A pharmaceutical composition related to drug delivery systems for the treatment of nail diseases includes (i) poloxamer 407, (ii) at least one penetration enhancer, and (iii) at least one solubilizing agent selected from the group consisting of cyclodextrins, hydrophilic polymers and mixtures thereof. The composition also includes (iv) at least one biologically active substance and (v) a vehicle comprising water and a C.sub.1-C.sub.3 alcohol or mixtures thereof.

A pharmaceutical composition related to drug delivery systems for the treatment of nail diseases includes (i) poloxamer 407, (ii) at least one penetration enhancer, and (iii) at least one solubilizing agent selected from the group consisting of cyclodextrins, hydrophilic polymers and mixtures thereof. The composition also includes (iv) at least one biologically active substance and (v) a vehicle comprising water and a C.sub.1-C.sub.3 alcohol or mixtures thereof.

The present invention relates to novel compounds that are autotaxin inhibitors, processes for their preparation, pharmaceutical compositions and medicaments containing them and to their use in diseases and disorders mediated by autotaxin. ##STR00001##

The present invention relates to novel compounds that are autotaxin inhibitors, processes for their preparation, pharmaceutical compositions and medicaments containing them and to their use in diseases and disorders mediated by autotaxin. ##STR00001##

The present invention relates to novel compounds that are autotaxin inhibitors, processes for their preparation, pharmaceutical compositions and medicaments containing them and to their use in diseases and disorders mediated by autotaxin. ##STR00001##

Disclosed are small molecules against cereblon to enhance effector T cell function. Methods of making these molecules and methods of using them to treat various disease states are also disclosed.

Disclosed are small molecules against cereblon to enhance effector T cell function. Methods of making these molecules and methods of using them to treat various disease states are also disclosed.